RecruitingNot ApplicableNCT06927206

Segmental Vibrator With NMES on Lower Limb Function in Subacute Stroke

Combined Effects of Segmental Vibrator With Neuromuscular Electrical Stimulation for Dorsiflexors on Lower Limb Function in Subacute Stroke


Sponsor

Riphah International University

Enrollment

50 participants

Start Date

Apr 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Stroke is one of the world's leading causes of death and disability. It can cause a variety of motor disorders, such as apraxia, sensory deficits, abnormal muscle tone, inadequate weight transfer, lack of fine motor skills, incoordination, and balance deficit. These disorders can have a significant negative impact on a person's quality of life.


Eligibility

Min Age: 45 YearsMax Age: 60 Years

Inclusion Criteria9

  • Both male and female patients were included in the study.
  • The age range of participants was between 45 and 60 years.
  • Participants that were diagnosed with ischemic stroke patient.
  • Participants had experienced sub-acute ischemic stroke, specifically 15 days to 12 weeks post-stroke.
  • Montreal Cognitive Assessment scores falling within the range of 18-24 were necessary.
  • Modified Ashworth scale scores had to be less than +1
  • National Institutes of Health Stroke Scale (NIHSS) score falling within the range of 1 to 15 were necessary.
  • Participants feel no pain from the vibrator.
  • It was anticipated that participants would either be able to give informed consent or have a legal representative who could do so.

Exclusion Criteria5

  • People who had a history of serious neurological or mental conditions that would have impeded lower limb motor recovery-aside from stroke-were not included.
  • Individuals with severe arthritis or joint injuries, among other illnesses that would have interfered with treatment or evaluations, were not allowed to participate.
  • Individuals who had significant hearing or vision impairments that would have hampered treatment or evaluations were not included.
  • Individuals undergoing anti-spatial therapy or other clinical trials, those with bilateral brain lesions, and those with ischemic involvement of the cerebellum or basal ganglia were not allowed to participate.
  • Participants having metal implants e. g cardiac pacemaker and skin lesion at the site of stimulation electrodes were excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERExperimental Group A: Segmental vibrator only on dorsiflexor

Segmental vibrator only on dorsiflexor: After standard physiotherapy session this group received the intervention of segmental vibration. Tibialis anterior muscle targeted for dorsiflexor. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator.

OTHERExperimental Group B: Segmental vibrator + Electrical stimulation on dorsiflexors

Segmental vibrator + Electrical stimulation on dorsiflexors: After standard physiotherapy session this group received the intervention of neuromuscular electrical stimulations by means of EMS. Two electrodes were used for this procedure. Tibialis anterior muscle targeted for dorsiflexor. One pad of electrode was placed on anterior of lower leg just below tibial tuberisty and other was 5cm below to it .With a 250-microsecond pulse duration, the EMS device was set up to provide a biphasic current with a symmetrical waveform at 50 Hz for 15 seconds. It was also tuned for a 3-second ramp up time and a 30-second rest period. Each respondent set the intensity to the highest level they could tolerate. Secondly, segmental vibrator was applied for focal vibrations on tibialis anterior. The segmental vibration of high frequency i.e 100 Hz and low amplitude (0.2-0.5mm) was applied at muscle belly for 10 min while interpersed with a 1 min break by mean of segmental vibrator.


Locations(1)

Jinnah Hospital

Lahore, Punjab Province, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06927206


Related Trials